Jan 24, 2014 by Amy HoUK Eyes Success of US FDA Breakthrough Designation ProgramExpedited review of drugs in UK would be a win for patients, even bigger win for investors
Jan 22, 2014 by Amy HoBristol-Myers Squibb Hepatitis C Therapy Opens Up Combination OptionsBristol-Myers Squibb breaks from seeking a combination with Gilead on hepatitis C treatment.
Jan 17, 2014 by Amy HoMerck & Co., Inc. Reinvigorates R&D With Emphasis On Cancer ImmunotherapyMerck's aggressive plan will likely spur competitors Roche and Bristol-Myers Squibb
Jan 15, 2014 by Amy HoAlnylam Partnership Signal Revitalizing of RNAi TherapeuticsMerck backs away while Sanofi ups its share.
Dec 13, 2013 by Amy HoFDA Takes Issue with Takeda's Prospective 2014 Approval of VedolizumabConcerns over infection risks spurred action from an FDA advisory panel regarding the approval of the inflammatory bowel disease treatment vedolizumab.
Dec 11, 2013 by Amy HoNovartis Strengthens in Oncology With Multiple Myeloma Novartis' strong R&D proves itself in the face of rivals' acquisitions and restructuring
Dec 10, 2013 by Amy HoGilead's Sofosbuvir Gains FDA Approval, Attracts Patent Battle Race for new hepatitis C therapy riddled with patent complications.
Dec 10, 2013 by Amy HoEli Lilly Struggles for Pipeline SuccessEdivoxetine failure dampens Lilly's R&D efforts
Dec 10, 2013 by Amy HoIclusig Troubles Continue for Ariad in EuropeAriad's leukemia agent struggles with European regulators after the FDA pulled its product.
Dec 4, 2013 by Amy HoMylan Nabs India, Roche Takes Europe in Breast Cancer TherapiesMylan and Biocon gain approval for Herceptin biosimilar in India while Roche and ImmunoGen gain approval for Herceptin-DM1 combination Kadcyla in Europe.
Dec 4, 2013 by Amy HoAstraZeneca Eyes Forest Labs as Shares RiseForest Laboratories makes significant company improvements as AstraZeneca considers possible buyout.
Dec 2, 2013 by Amy HoRepros Poised to Take On Growing Testosterone MarketRepros wins meeting with FDA for oral testosterone frontrunner Androxal after FDA concerns last month tanked shares
Nov 11, 2013 by Amy HoPotential for Anti-NGF Agents Builds With Partnership Between Pfizer and Eli LillyPfizer and Eli Lilly collaboration may mark new beginnings for high-risk class of drugs
Nov 6, 2013 by Amy HoTroubled Merck Puts Hopes in New HPV VaccineMerck announces positive phase 3 results for its next-generation HPV vaccine V503.
Nov 5, 2013 by Amy HoBristol-Myers Squibb First to Japan in New Hepatitis C Therapy RaceBristol-Myers Squibb files for approval in Japan of first ever all-oral and interferon- and ribavirin-free hepatitis C treatment.
Nov 4, 2013 by Amy HoRoche's Gazyva Approval Marks Success in Oncology and New FDA DesignationThe FDA's first therapy given the Breakthrough Therapy designation gains approval, paving the way for competitors.
Nov 1, 2013 by Amy HoGilead Sciences and Johnson & Johnson Push Vertex Out of Hepatitis C RaceVertex announces job cuts and focus towards cystic fibrosis amid Food and Drug Administration moves on competiting hepatitis C therapies.
Nov 1, 2013 by Amy HoFDA Approves New Alzheimer's Diagnostic Agent but Medicare and Markets Yet to FollowA look at GE (NYSE: GE) Healthcare's newly-approved Alzheimer's imaging agent, and other players in this space like Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), and Navidea Biopharmaceuticals (NYSEMRK: NAVB).
Oct 31, 2013 by Amy HoNutrisystem Earnings Bulk Up the Weight-Loss SpaceWeight-loss companies Nutrisystem, Weight Watchers and Medifast face unique challenges as consumers fatten up for diet season.
Oct 30, 2013 by Amy HoPfizer Earnings Report Rounds Out Dow Pharmaceuticals OutlookPfizer falls in middle of struggling Merck and stable Johnson & Johnson in recent big pharma earnings reports.
